In the 2015 Federal election, the Liberal Party of Canada ran on a platform that included the legalization of recreational cannabis. Following the election, a task force was created to report on legalization and regulation, and a report was delivered in November 2016. On April 13, 2017, Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts (the "Cannabis Act") was introduced, largely implementing the recommendations of the task force. In a nutshell, it decriminalizes the possession of certain amounts of cannabis and makes allowance for production for commercial use.
The Bill introduces a system of licensing and permitting for the production, distribution and sale of "licit" cannabis; any cannabis produced, distributed or sold other than as permitted in the Act or any provincial Act is considered "illicit". Good news to those who invested resources to submit applications for licensing under the medical marijuana regime (formerly the MMPR, now the Access to Cannabis for Medical Purposes Regulations ("ACMPR")): the transitional provisions of the Bill provide that any licence issued, or application in process under that regime will be deemed a licence or application under the Cannabis Act when it comes into force.
The Bill does not speak to the mechanics of distribution. Instead, it provides that a person may possess, sell or distribute cannabis if that person is authorized to do so under a provincial Act. The Bill does note though that a person can only sell cannabis under provincial Act if the cannabis was produced by a person authorized under the Cannabis Act to produce for commercial purposes. Thus, we should expect additional information from the provinces regarding the model for sale of cannabis.
Of particular interest to some is whether or not any provincial legislation will allow for the distribution of medical cannabis by pharmacies – something that was a hot issue when medicinal cannabis regulations were first introduced (currently, medicinal cannabis can only be distributed through the mail). The Bill proposes that separate access to cannabis for medical purposes be maintained, and the ACMPR will continue to be in effect. It remains to be seen how, if at all, the soon-to-come provincial legislation will impact the distribution of medical cannabis.
Highlights of the Bill are set out below:
The Cannabis Act provides for a licensing and permit scheme for the production, testing, packaging, labelling, sending, delivery, transportation, sale, possession or disposal of commercial cannabis. Although details will be governed by yet-to-be-developed regulations, it appears that the process will be similar to that currently in place under the ACMPR. Requirements will likely relate primarily to safety and security, and provide product standards for cannabis sold.
As set out above, the Bill provides that several types of licenses and permits issued or applied for under other acts and regulations at the date the new Act comes into force will be deemed to be issued under the Cannabis Act. These include producers licenses, import and export permits, and security clearances issued under the ACMPR as well as narcotic dealers licenses for those that deal in cannabis under the Narcotic Control Regulations.
It is proposed that cannabis can only be imported or exported pursuant to a license, and only then for medical or scientific purposes.
What can be sold
Only cannabis produced pursuant to a license can be sold, and products containing cannabis in combination with nicotine, caffeine or alcohol will be prohibited. The government anticipates that on the coming into force of the Cannabis Act commercial products will be limited to fresh and dried cannabis, cannabis oil, seeds and plants. Further regulation may allow for the sale of edibles and other products, however these are not anticipated to be in place initially.
Packaging & Labelling
Packaging and labelling requirements will be determined primarily by yet-to-be-developed regulations. The Bill provides that packaging must not be false, misleading or deceptive, and it must also not be appealing to young persons, contain testimonials or endorsements, depict persons or characters, or associate a product with certain lifestyle imagery.
The Bill permits information-type promotion, restricted to factual and accurate information about cannabis products (ingredients, THC and CBD levels, etc.). Information that allows consumers to tell the difference between brands will also be permitted. Promotion is only allowed where it will not be seen by young persons.
There are proposed restrictions on advertising relating to sponsorship, endorsements and testimonials, price, depiction of persons or characters, lifestyle advertising, and advertising in a way that could be appealing to young persons. The Cannabis Act provides for regulation making powers and regulations could affect what is permitted or require the inclusion of specific information such as health risk information.
It is expected that the government will amend the Excise Tax Act in order to tax cannabis. The task force report suggested taxing higher-potency THC at a higher rate, and using revenue generated from the sale of cannabis for drug prevention, education and treatment goals.
The Government of Canada has set a target date of July 2018 for a recreational cannabis market, however Bill C-45 has only just been introduced and must be passed by both houses. Further, many aspects of the regulatory regime will be determined by regulation and these regulations need to be drafted and published. There are therefore no guarantees as to if, when, or how cannabis will be legalized and regulated. Until the Cannabis Act is in force, existing laws remain in place and the provisions discussed above are subject to change.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.